Fenitab 200 mg (Tablet)
Unit Price: ৳ 300.00 (7 x 4: ৳ 8,400.00)
Strip Price: ৳ 1,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sorafenib tosylate |
| Company | Eskayef pharmaceuticals ltd |
Indications
- Unresectable hepatocellular carcinoma treatment
- Advanced renal cell carcinoma treatment
Pharmacology
- Kinase inhibitor
- Decreases tumor cell proliferation
- Inhibits multiple intracellular and cell surface kinases
- Involved in tumor cell signaling, angiogenesis, and apoptosis
- Inhibited tumor growth and angiogenesis
Dosage & Administration
- Recommended daily dose of 400 mg tablets
- Taken twice daily without food
- Treatment duration until clinical benefit stops or unacceptable toxicity occurs
- Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction
- No dose adjustment based on patient age, gender, or body weight
- Missed dose management
Interaction
- Contraindications and precautions with various medications
- Systemic exposure to substrates may increase when co-administered with Fenitab
- Impact on CYP enzymes, P-glycoprotein and neomycin
- Effect on antineoplastic agents and metabolism
- Inhibition of P-glycoprotein
Contraindications
- Severe hypersensitivity to Fenitab or any other component
- Contraindicated in patients with squamous cell lung cancer when combined with carboplatin and paclitaxel
Side Effects
- Cardiac ischemia, infarction
- Hemorrhage
- Hypertension
- Hand-foot skin reaction and rash
- Gastrointestinal perforation
- Wound healing complications
Pregnancy & Lactation
- May cause fetal harm when administered to a pregnant woman
- Women of childbearing potential advised to avoid pregnancy while on Fenitab
- Excretion in human milk not known
Precautions & Warnings
- Consideration of discontinuation in case of cardiac ischemia and/or infarction
- Increased risk of bleeding and hypertension
- Common adverse reactions related to skin and gastrointestinal system
- Consideration for concomitant warfarin use
- Impact on wound healing following a major surgical intervention
Use in Special Populations
- Safety and effectiveness not studied in pediatric patients
- No differences in safety or efficacy between older and younger patients
- No dose adjustment required for renal impairment
- Impact of hepatic impairment on systemic exposure
Overdose Effects
- No specific treatment for overdose
- Observed adverse reactions at highest clinical dose
Therapeutic Class
- Targeted cancer therapy
Storage Conditions
- Store at room temperature below 30°C
- Dispense in original bottle